Clinical Trials Sponsored by Jason J. Luke, MD

Total 11 results

Jason J. Luke, MD

Recruiting

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Melanoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | Cholangiocarcinoma | Bladder Cancer | Renal Cancer | Anal Cancer | Merkel Cell Carcinoma | HNSCC

United States
Jason J. Luke, MD
Array BioPharma

Active, not recruiting

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Jason J. Luke, MD
Bristol-Myers Squibb

Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Unresectable Solid Tumors

United States
Jason J. Luke, MD
Bristol-Myers Squibb

Active, not recruiting

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)

Melanoma

United States
Jason J. Luke, MD
Bristol-Myers Squibb; Agios Pharmaceuticals, Inc.

Completed

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Glioma | Advanced Solid Tumor | IDH1 Mutation

United States
Luke, Jason, MD
Lumos Pharma

Withdrawn

Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

Advanced Solid Tumors
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Andrew J. Armstrong, MD

Completed

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Prostate Cancer

United States
Andrew J. Armstrong, MD

Completed

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC)

Prostate Cancer

United States
Andrew J. Armstrong, MD
Novartis Pharmaceuticals

Terminated

BKM120 in Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Metastatic (Spread to Other Areas of the Body)

United States
Andrew J. Armstrong, MD
Bristol-Myers Squibb

Recruiting

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)

Metastatic Prostate Cancer | Metastatic Prostate Neuroendocrine Carcinoma

United States

Clinical Trials Sponsored by Jason J. Luke, MD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations